Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising.
Adaptogenics (CSE: ADPT) is positioning to capitalize on potential changes in U.S. peptide regulations that could expand access through specialty pharmacies and telehealth platforms. As the FDA considers allowing additional peptides for pharmacy compounding, the company plans to differentiate itself by developing proprietary peptide formulations and delivery technologies designed to improve stability, absorption, administration and performance. Adaptogenics has also acquired nutritional research assets from Berkwood Research to support a GLP-1 companion initiative focused on preserving muscle mass, strength and metabolic health during medically induced weight loss. Recent leadership additions, including healthcare dealmaking executive Antoun Nabhan as president and Dr. Robert Bergia as a scientific advisor, are expected to support research, licensing, acquisitions and strategic partnerships.
To view the full article, visit https://ibn.fm/ZENA
About Adaptogenics Health Corp.
Adaptogenics is building a science led company focused on identifying, acquiring, designing and advancing proprietary peptide and small molecule programs. The company is evaluating opportunities in metabolic health, muscle preservation, mitochondrial biology and inflammation, including delivery technologies intended to improve the performance of promising molecules. The company will continue its existing nutraceutical operations while evaluating GLP 1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies and reduced physical function.
NOTE TO INVESTORS: The latest news and updates relating to ADPT are available in the company’s newsroom at https://ibn.fm/ADPT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Nanox (NASDAQ: NNOX) announced plans to showcase its medical imaging technologies at the Radiological Society…
Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended…
Nutriband (NASDAQ: NTRB) announced that it received a Notice of Allowance dated Nov. 3, 2026,…
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid…
This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…
Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…